Skip to main content

Mitchell Shawnte's Form 4 filing

Olema Pharmaceuticals, Inc. (OLMA) · filed Mar 5, 2026

Accession no.
0001749432-26-000004
Filed
Mar 5, 2026
Trade date
Mar 3-4, 2026
Filing delay
2 days
Rule 10b5-1 plan
Not checked

This filing lists 5 non-derivative transactions and 2 derivative transactions. Open-market sales total $951.5K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Mitchell ShawnteCIK 0001749432Officer (CHIEF LEGAL OFFICER)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Mar 3, 2026Common StockMOption exerciseAcquired+15,000$4.37+$65,55015,000Direct
Mar 3, 2026Common StockSSaleDisposed−15,000$23.01−$345,1500Direct
Mar 4, 2026Common StockMOption exerciseAcquired+25,000$4.37+$109,25025,000Direct
Mar 4, 2026Common StockSSaleDisposed−24,767$24.25−$600,599.75233Direct
Mar 4, 2026Comon StockSSaleDisposed−233$24.69−$5,752.770Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Mar 3, 2026Common StockMOption exerciseDisposed−15,000$0.00$0435,000Direct
Mar 4, 2026Common StockMOption exerciseDisposed−25,000$0.00$0410,000Direct

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)